Sector Expert: Stewart Washer
Stewart Washer has 20 years of CEO and board experience in medical technology, biotech and agrifood companies. He is currently the chairman of Orthocell Ltd., which cultures tendon cells to repair damaged tendons, chairman of Cynata Therapeutics Ltd., which is developing stem cell therapies, and chairman of Minomic International Ltd., which has an accurate noninvasive test for prostate cancer. He was also a founder of a NZ$120M New Zealand-based life science fund and venture partner with the Swiss-based Inventages Nestlé Fund. He is currently investment director with Bioscience Managers.
Advanced Stem Cell Manufacture Saves Lives and Prints Money: Stewart Washer of Cynata Therapeutics (2/3/16)
Cynata Therapeutics of Australia has carved a technological niche in the fast-advancing cell therapy market with a platform that renders the production of stem cell-based treatments for cancer and diseases of the immune system easy and affordable, saving lives and money. In this interview, Cynata's executive chairman Stewart Washer tells The Life Sciences Report why his company's technology, in studies for graft-versus-host disease, has proven itself a profit driver.